Bone Biologics Appoints Robert E. Gagnon to Board of Directors
Bone Biologics Announces 1-for-8 Reverse Stock Split
Bone Biologics Corp., a developer of orthobiologic products for spine fusion markets, has engaged Avania as the contract research organization (CRO) for the Company’s clinical trial with NB1. Avania is an integrated global, full-service CRO with specialized expertise in medical devices, novel technology and drug-device combination products. The trial will evaluate the safety and effectiveness of Bone Biologic’s novel NB1 in patients with degenerative disc disease undergoing a Transforaminal Lumbar Interbody Fusion (TLIF) procedure.
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company plans to use the net proceeds to fund its planned clinical trials, maintain and extend its patent portfolio, retain contract research organizations, and for working capital and other general corporate purposes.
Bone Biologics (OTCPK:BBLG -30.4%) prices the stock offering of its 1,510,455 units at $5.25 per unit with underwriters overallotment option